AU2021380319B2 - Pharmaceutical composition for oral administration of edaravone and method of administering same - Google Patents

Pharmaceutical composition for oral administration of edaravone and method of administering same Download PDF

Info

Publication number
AU2021380319B2
AU2021380319B2 AU2021380319A AU2021380319A AU2021380319B2 AU 2021380319 B2 AU2021380319 B2 AU 2021380319B2 AU 2021380319 A AU2021380319 A AU 2021380319A AU 2021380319 A AU2021380319 A AU 2021380319A AU 2021380319 B2 AU2021380319 B2 AU 2021380319B2
Authority
AU
Australia
Prior art keywords
administration
meal
edaravone
hours
consumption
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021380319A
Other languages
English (en)
Other versions
AU2021380319A1 (en
Inventor
Yoshinobu NAKAMARU
Yukiko Nishimura
Hidetoshi Shimizu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=81602356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2021380319(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Publication of AU2021380319A1 publication Critical patent/AU2021380319A1/en
Application granted granted Critical
Publication of AU2021380319B2 publication Critical patent/AU2021380319B2/en
Priority to AU2025203773A priority Critical patent/AU2025203773A1/en
Assigned to Tanabe Pharma Corporation reassignment Tanabe Pharma Corporation Request to Amend Deed and Register Assignors: MITSUBISHI TANABE PHARMA CORPORATION
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021380319A 2020-11-12 2021-11-12 Pharmaceutical composition for oral administration of edaravone and method of administering same Active AU2021380319B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025203773A AU2025203773A1 (en) 2020-11-12 2025-05-22 Pharmaceutical composition for oral administration of edaravone and method of administering same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020188514 2020-11-12
JP2020-188514 2020-11-12
PCT/JP2021/041673 WO2022102737A1 (ja) 2020-11-12 2021-11-12 エダラボン経口投与用医薬組成物およびその投与方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025203773A Division AU2025203773A1 (en) 2020-11-12 2025-05-22 Pharmaceutical composition for oral administration of edaravone and method of administering same

Publications (2)

Publication Number Publication Date
AU2021380319A1 AU2021380319A1 (en) 2023-06-22
AU2021380319B2 true AU2021380319B2 (en) 2025-03-20

Family

ID=81602356

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021380319A Active AU2021380319B2 (en) 2020-11-12 2021-11-12 Pharmaceutical composition for oral administration of edaravone and method of administering same
AU2025203773A Pending AU2025203773A1 (en) 2020-11-12 2025-05-22 Pharmaceutical composition for oral administration of edaravone and method of administering same

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025203773A Pending AU2025203773A1 (en) 2020-11-12 2025-05-22 Pharmaceutical composition for oral administration of edaravone and method of administering same

Country Status (11)

Country Link
US (2) US11911366B2 (cg-RX-API-DMAC7.html)
EP (1) EP4245303A4 (cg-RX-API-DMAC7.html)
JP (2) JPWO2022102737A1 (cg-RX-API-DMAC7.html)
KR (1) KR20230098267A (cg-RX-API-DMAC7.html)
CN (1) CN116761601A (cg-RX-API-DMAC7.html)
AR (1) AR124062A1 (cg-RX-API-DMAC7.html)
AU (2) AU2021380319B2 (cg-RX-API-DMAC7.html)
CA (1) CA3198014A1 (cg-RX-API-DMAC7.html)
IL (1) IL302533A (cg-RX-API-DMAC7.html)
TW (1) TW202228678A (cg-RX-API-DMAC7.html)
WO (1) WO2022102737A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024036261A2 (en) * 2022-08-10 2024-02-15 Kpr U.S., Llc Occlusion detection system and method for a flow control apparatus
EP4559463A1 (en) * 2023-11-23 2025-05-28 Ferrer Internacional, S.A. Edaravone or its salts for use in the treatment of oxidative stress-mediated neurodegenerative disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190083463A1 (en) * 2016-03-16 2019-03-21 Suzhou Auzone Biological Technology Co., Ltd. Edaravone dosage form
US20190328712A1 (en) * 2017-01-17 2019-10-31 Treeway Tw001 B.V. Treatment comprising oral or gastric administration of edaravone
WO2020091036A1 (ja) * 2018-11-02 2020-05-07 田辺三菱製薬株式会社 経口投与用エダラボン懸濁剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61263917A (ja) 1985-05-20 1986-11-21 Mitsubishi Yuka Yakuhin Kk 脳機能正常化剤
JPH0531523A (ja) 1991-07-26 1993-02-09 Aichi Steel Works Ltd ロ−ラ回転数・間隙測定可能な圧延機用ロ−ラガイド装置
ES2248144T3 (es) 2000-10-24 2006-03-16 Mitsubishi Pharma Corporation Medicamentos para tratar la esclerosis lateral amiotrofica (ela).
CN110381923A (zh) * 2017-01-17 2019-10-25 萃微Tw001公司 包括肠内施用依达拉奉的医学治疗
JP7012792B2 (ja) 2020-08-06 2022-01-28 株式会社 ディー・エヌ・エー 動画を配信するためのシステム、方法、及びプログラム
US12194025B2 (en) 2020-11-12 2025-01-14 Mitsubishi Tanabe Pharma Corporation Pharmaceutical composition for oral administration of edaravone and method of administering same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190083463A1 (en) * 2016-03-16 2019-03-21 Suzhou Auzone Biological Technology Co., Ltd. Edaravone dosage form
US20190328712A1 (en) * 2017-01-17 2019-10-31 Treeway Tw001 B.V. Treatment comprising oral or gastric administration of edaravone
WO2020091036A1 (ja) * 2018-11-02 2020-05-07 田辺三菱製薬株式会社 経口投与用エダラボン懸濁剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Takei, K et al., 'Radicava (edaravone) for Amyotrophic Lateral Slerosis: New Formulation and Its Development Plan (P1.4-014)', Neurology, 2019, vol. 92, no. 15 supplement. *

Also Published As

Publication number Publication date
US12478611B2 (en) 2025-11-25
TW202228678A (zh) 2022-08-01
US20220142982A1 (en) 2022-05-12
JPWO2022102737A1 (cg-RX-API-DMAC7.html) 2022-05-19
IL302533A (en) 2023-07-01
US11911366B2 (en) 2024-02-27
CN116761601A (zh) 2023-09-15
AU2025203773A1 (en) 2025-06-12
WO2022102737A1 (ja) 2022-05-19
KR20230098267A (ko) 2023-07-03
US20240173297A1 (en) 2024-05-30
AR124062A1 (es) 2023-02-08
EP4245303A4 (en) 2024-10-09
CA3198014A1 (en) 2022-05-19
EP4245303A1 (en) 2023-09-20
JP2025061070A (ja) 2025-04-10
AU2021380319A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
AU2025203773A1 (en) Pharmaceutical composition for oral administration of edaravone and method of administering same
US12527769B2 (en) Pharmaceutical composition for oral administration of edaravone and method of administering same
BRPI0707277B1 (pt) Composição, uso da mesma,e , formulação famacêutica
EP2754440B1 (en) Medicinal agent for treating amyotrophic lateral sclerosis or preventing progression of phase of amyotrophic lateral sclerosis
US20150320712A1 (en) Nutritional Composition for Gastrostomy-Tube Patients
US12491178B2 (en) Stable pharmaceutical compositions of edaravone
CN109922801A (zh) 甲硝唑和巴氯芬的混悬剂和稀释剂
BR112017027636B1 (pt) Composições nutricionais líquidas ou semilíquidas e composições nutricionais
EP4559463A1 (en) Edaravone or its salts for use in the treatment of oxidative stress-mediated neurodegenerative disorders
US12558347B2 (en) Cevimeline liquid formulations
WO2021079987A1 (ja) 筋質向上剤
US20260102351A1 (en) Lyophilized formulation of crofelemer and methods of treatment using the same
JP2010265186A (ja) 貧血予防用組成物
US20260027067A1 (en) Trientine liquid dosage forms
CN116763726A (zh) 一种盐酸西替利嗪口服溶液及其制备方法
KR20160004482A (ko) 몬테루카스트 또는 이의 약제학적으로 허용가능한 염의 경구투여용 액상제제

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAME

FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: TANABE PHARMA CORPORATION

Free format text: FORMER NAME(S): MITSUBISHI TANABE PHARMA CORPORATION